This figure depicts the analytic framework that outlines the population, interventions and outcomes considered in the review. The above figure is a modified version of a larger framework depicting the impact of both screening and treatment for Hepatitis C in adults. This figure focuses on the treatment portion of the framework. The population includes Adults with chronic hepatitis C virus (HCV) infection. The interventions include pegylated interferon alfa-2a with ribavirin; pegylated interferon alfa-2b with ribavirin; protease inhibitors pending FDA approval (e.g., telaprevir). Intermediate outcomes include liver function, sustained virologic remission, and histologic changes. Final outcomes include morbidity and mortality from HCV (ncluding hepatic cirrhosis, hepatocellular carcinoma, liver transplantation rates, quality of life); harms of antiviral therapies including flu-like symptoms, hematologic effects, psychiatric effects.

Figure 1Analytic framework for treatment of hepatitis C infection in adults

KQ = Key Question

From: Introduction

Cover of Treatment for Hepatitis C Virus Infection in Adults
Treatment for Hepatitis C Virus Infection in Adults [Internet].
Comparative Effectiveness Reviews, No. 76.
Chou R, Hartung D, Rahman B, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.